{"id":66095,"date":"2026-01-19T19:20:24","date_gmt":"2026-01-19T13:50:24","guid":{"rendered":"https:\/\/johnsonfrancis.org\/professional\/?p=66095"},"modified":"2026-01-19T19:20:28","modified_gmt":"2026-01-19T13:50:28","slug":"ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors","status":"publish","type":"post","link":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/","title":{"rendered":"CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors"},"content":{"rendered":"<iframe loading=\"lazy\" width=\"560\" height=\"315\" src=\"https:\/\/www.youtube.com\/embed\/0AT_Ahwwzck?si=DTxaW3oDDCVNLGjL\" title=\"YouTube video player\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe>\n\n<p class=\"wp-block-paragraph\">In the CCU, the goal for vasopressors and inotropes in cardiogenic shock (CS) is to bridge the patient to definitive therapy (revascularization or MCS) while maintaining organ perfusion without excessively increasing myocardial oxygen demand (MVO<sub>2<\/sub>).<\/p>\n\n\n\n<h3 class=\"wp-block-heading\">1. The First-Line Vasopressor: Norepinephrine<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Why:<\/strong> Lower risk of arrhythmias compared to dopamine (<a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa0907118\">SOAP II trial<\/a>).<\/li>\n\n\n\n<li class=\"\"><strong>Action:<\/strong> Predominantly \u03b1<sub>1<\/sub> (vasoconstriction) with moderate \u03b2<sub>1<\/sub> (inotropy).<\/li>\n\n\n\n<li class=\"\"><strong>Goal:<\/strong> Maintain MAP \u2265 65 mmHg.<\/li>\n\n\n\n<li class=\"\"><strong>Caveat:<\/strong> Avoid <strong>Epinephrine<\/strong> as a first-line agent if possible; it is associated with higher rates of refractory shock, lactic acidosis, and increased MVO<sub>2<\/sub>.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">2. Adding Inotropy: Dobutamine vs. Milrinone<\/h3>\n\n\n\n<p class=\"wp-block-paragraph\">If the MAP is stable but cardiac output remains low (cold extremities, rising lactate), add an &#8220;inodilator.&#8221;<\/p>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><td><strong>Agent<\/strong><\/td><td><strong>Mechanism<\/strong><\/td><td><strong>Pros<\/strong><\/td><td><strong>Cons<\/strong><\/td><\/tr><\/thead><tbody><tr><td><strong>Dobutamine<\/strong><\/td><td>\u03b2<sub>1<\/sub> > \u03b2<sub>2<\/sub> agonist<\/td><td>Rapid onset\/offset; titratable.<\/td><td>Tachyarrhythmias; increases MVO<sub>2<\/sub>.<\/td><\/tr><tr><td><strong>Milrinone<\/strong><\/td><td>PDE-3 Inhibitor<\/td><td>Works &#8220;downstream&#8221; of \u03b2-blockers; less tachycardia.<\/td><td>Long half-life (hard to &#8220;turn off&#8221;); significant hypotension; renally cleared.<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong><a href=\"https:\/\/www.nejm.org\/doi\/full\/10.1056\/NEJMoa2026845\">DOREMI Trial<\/a> (2021):<\/strong> Showed no significant difference in 30-day mortality between the two.<\/li>\n\n\n\n<li class=\"\"><strong>Clinical Pearl:<\/strong> Choose <strong>Milrinone<\/strong> for patients on chronic \u03b2-blockers or with pulmonary hypertension\/RV failure. Choose <strong>Dobutamine<\/strong> for patients with renal impairment or those prone to hypotension.<\/li>\n<\/ul>\n\n\n\n<h3 class=\"wp-block-heading\">3. Quick Checklist for Titration<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li class=\"\"><strong>Is the SVR high?<\/strong> (The &#8220;Cold and Wet&#8221; patient). Prioritize inotropy and consider afterload reduction (nitroprusside) if BP allows.<\/li>\n\n\n\n<li class=\"\"><strong>Is there Vasoplegia?<\/strong> (Low SVR despite low CO). Use <strong>Norepinephrine<\/strong> + <strong>Vasopressin<\/strong> (to spare catecholamine dose).<\/li>\n\n\n\n<li class=\"\"><strong>Is it &#8220;SCAI Stage D\/E&#8221;?<\/strong> If you are maxing out two pressors\/inotropes, pharmacological therapy has likely failed. Escalate immediately to <strong>Mechanical Circulatory Support (MCS)<\/strong> (e.g., Impella, IABP, or ECMO).<\/li>\n<\/ul>\n\n\n\n<hr class=\"wp-block-separator has-alpha-channel-opacity\"\/>\n","protected":false},"excerpt":{"rendered":"<p>In the CCU, the goal for vasopressors and inotropes in cardiogenic shock (CS) is to bridge the patient to definitive therapy (revascularization or MCS) while maintaining organ perfusion without excessively increasing myocardial oxygen demand (MVO2). 1. The First-Line Vasopressor: Norepinephrine 2. Adding Inotropy: Dobutamine vs. Milrinone If the MAP is stable but cardiac output remains [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":66099,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"nf_dc_page":"","footnotes":""},"categories":[9],"tags":[],"class_list":["post-66095","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.9 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors - All About Cardiovascular System and Disorders<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors - All About Cardiovascular System and Disorders\" \/>\n<meta property=\"og:description\" content=\"In the CCU, the goal for vasopressors and inotropes in cardiogenic shock (CS) is to bridge the patient to definitive therapy (revascularization or MCS) while maintaining organ perfusion without excessively increasing myocardial oxygen demand (MVO2). 1. The First-Line Vasopressor: Norepinephrine 2. Adding Inotropy: Dobutamine vs. Milrinone If the MAP is stable but cardiac output remains [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/\" \/>\n<meta property=\"og:site_name\" content=\"All About Cardiovascular System and Disorders\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-19T13:50:24+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-19T13:50:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/CCU-Consult-Quick-Refresher-on-Managing-Cardiogenic-Shock-Pressors.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"677\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Johnson Francis\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Johnson Francis\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/\"},\"author\":{\"name\":\"Johnson Francis\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"headline\":\"CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors\",\"datePublished\":\"2026-01-19T13:50:24+00:00\",\"dateModified\":\"2026-01-19T13:50:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/\"},\"wordCount\":255,\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/CCU-Consult-Quick-Refresher-on-Managing-Cardiogenic-Shock-Pressors.jpg\",\"articleSection\":[\"General Cardiology\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/\",\"name\":\"CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors - All About Cardiovascular System and Disorders\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/CCU-Consult-Quick-Refresher-on-Managing-Cardiogenic-Shock-Pressors.jpg\",\"datePublished\":\"2026-01-19T13:50:24+00:00\",\"dateModified\":\"2026-01-19T13:50:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/#primaryimage\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/CCU-Consult-Quick-Refresher-on-Managing-Cardiogenic-Shock-Pressors.jpg\",\"contentUrl\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/wp-content\\\/uploads\\\/2026\\\/01\\\/CCU-Consult-Quick-Refresher-on-Managing-Cardiogenic-Shock-Pressors.jpg\",\"width\":1200,\"height\":677},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#website\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/\",\"name\":\"All About Cardiovascular System and Disorders\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":[\"Person\",\"Organization\"],\"@id\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/#\\\/schema\\\/person\\\/5441d907049b914770f4bd98fb57feec\",\"name\":\"Johnson Francis\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\",\"caption\":\"Johnson Francis\"},\"logo\":{\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g\"},\"description\":\"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal\",\"url\":\"https:\\\/\\\/johnsonfrancis.org\\\/professional\\\/author\\\/jf\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors - All About Cardiovascular System and Disorders","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/","og_locale":"en_US","og_type":"article","og_title":"CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors - All About Cardiovascular System and Disorders","og_description":"In the CCU, the goal for vasopressors and inotropes in cardiogenic shock (CS) is to bridge the patient to definitive therapy (revascularization or MCS) while maintaining organ perfusion without excessively increasing myocardial oxygen demand (MVO2). 1. The First-Line Vasopressor: Norepinephrine 2. Adding Inotropy: Dobutamine vs. Milrinone If the MAP is stable but cardiac output remains [&hellip;]","og_url":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/","og_site_name":"All About Cardiovascular System and Disorders","article_published_time":"2026-01-19T13:50:24+00:00","article_modified_time":"2026-01-19T13:50:28+00:00","og_image":[{"width":1200,"height":677,"url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/CCU-Consult-Quick-Refresher-on-Managing-Cardiogenic-Shock-Pressors.jpg","type":"image\/jpeg"}],"author":"Johnson Francis","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Johnson Francis","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/#article","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/"},"author":{"name":"Johnson Francis","@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"headline":"CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors","datePublished":"2026-01-19T13:50:24+00:00","dateModified":"2026-01-19T13:50:28+00:00","mainEntityOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/"},"wordCount":255,"publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/CCU-Consult-Quick-Refresher-on-Managing-Cardiogenic-Shock-Pressors.jpg","articleSection":["General Cardiology"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/","url":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/","name":"CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors - All About Cardiovascular System and Disorders","isPartOf":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#website"},"primaryImageOfPage":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/#primaryimage"},"image":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/#primaryimage"},"thumbnailUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/CCU-Consult-Quick-Refresher-on-Managing-Cardiogenic-Shock-Pressors.jpg","datePublished":"2026-01-19T13:50:24+00:00","dateModified":"2026-01-19T13:50:28+00:00","breadcrumb":{"@id":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/#primaryimage","url":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/CCU-Consult-Quick-Refresher-on-Managing-Cardiogenic-Shock-Pressors.jpg","contentUrl":"https:\/\/johnsonfrancis.org\/professional\/wp-content\/uploads\/2026\/01\/CCU-Consult-Quick-Refresher-on-Managing-Cardiogenic-Shock-Pressors.jpg","width":1200,"height":677},{"@type":"BreadcrumbList","@id":"https:\/\/johnsonfrancis.org\/professional\/ccu-consult-quick-refresher-on-managing-cardiogenic-shock-pressors\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/johnsonfrancis.org\/professional\/"},{"@type":"ListItem","position":2,"name":"CCU Consult: Quick Refresher on Managing Cardiogenic Shock Pressors"}]},{"@type":"WebSite","@id":"https:\/\/johnsonfrancis.org\/professional\/#website","url":"https:\/\/johnsonfrancis.org\/professional\/","name":"All About Cardiovascular System and Disorders","description":"","publisher":{"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/johnsonfrancis.org\/professional\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":["Person","Organization"],"@id":"https:\/\/johnsonfrancis.org\/professional\/#\/schema\/person\/5441d907049b914770f4bd98fb57feec","name":"Johnson Francis","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g","caption":"Johnson Francis"},"logo":{"@id":"https:\/\/secure.gravatar.com\/avatar\/80861b82c3f559be9e413245c5643b6c483c93495507facfe32cf96ccd8bcffd?s=96&d=mm&r=g"},"description":"Former Professor of Cardiology, Calicut Govt. Medical Kozhikode, Kerala, India. Editor-in-Chief, BMH Medical Journal","url":"https:\/\/johnsonfrancis.org\/professional\/author\/jf\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66095","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/comments?post=66095"}],"version-history":[{"count":4,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66095\/revisions"}],"predecessor-version":[{"id":66100,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/posts\/66095\/revisions\/66100"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media\/66099"}],"wp:attachment":[{"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/media?parent=66095"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/categories?post=66095"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/johnsonfrancis.org\/professional\/wp-json\/wp\/v2\/tags?post=66095"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}